Makoto™ Intravascular Imaging System
IVUS + NIRS Logos
Infraredx Clarispro™ Logos
The Heart Is Everything
OKAY® II Y-Connector
Dr. Giulio Guagliumi and Dr. Tina Vilsbøll discuss how intravascular imaging can enhance the continuum of care.
EuroPCR 2020 e-Course
featuring Dr. Giulio Guagliumi discussing the "Use of IVUS + NIRS imaging for decision making in Acute Coronary Syndrome."
Prospect II: A Prospective Natural History Study
Prospect II: A Prospective Natural History Study Using NIRS-IVUS Imaging in Patients with Acute Myocardial Infarction
Webinar: Clinical Innovations in IVUS NIRS Imaging
The first installment of the Infraredx, a Nipro Company, webinar series features Dr. Giulio Guagliumi of Ospedale Papa Giovanni XXIII in Bergamo, Italy, discussing "Clinical Innovations in IVUS+NIRS Imaging."
Approach to Patients with Polyvascular Disease: A Concerted Approach to Improve Outcomes
This virtual CME-accredited program is an approach to patients with polyvascular disease and improving outcomes. Topics include the role of PCSK9I and antithrombotic therapies; establishing a viable and integrated multi-disciplinary team to manage patients with CLI, and new advances in polyvascular disease research.
How To Optimally Use Intravascular Coronary Imaging and Coronary Physiology
This virtual CME-accredited program is designed to help healthcare professionals optimally use intravascular and coronary imaging as well as coronary physiology. View the webinar by clicking the link below.
Part I: Presented by David Erlinge, MD
Identification of Vulnerable Plaque: From PROSPECT to LRP and PROSPECT II
Part II: Presented by Lorenz Räber, MD
Pharmacologic Treatment of Vulnerable Plaque: Background and the PACMAN AMI Study
Part III: Presented by Gregg Stone, MD
Interventional Treatment of Vulnerable Plaque: Insights from PROSPECT ABSORB
Part IV: Panel Discussion
OPCI Journal Club: A Conversation with Dr. Räber - "The PACMAN-AMI Randomized Clinical Trial"
ACC 22: PACMAN-AMI Randomized Clinical Trial
PACMAN-AMI Shows Reduced Plaque Regression in AMI Patients Treated with Alirocumab